Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results

被引：0
|
作者：
Izzo, F.
Catino, A. M.
Vogl, T. J.
Middleton, M.
Valle, J. W.
Fiore, F.
Gadaleta, C. D.
Pirotta, R. M.
Martignoni, M.
Laffranchi, B.
机构：
[1] NCI, Fdn G Pascale, Naples, Italy
[2] IRCCS Osped Oncol, Bari, Italy
[3] Hosp Johann Wolfgang Goethe Univ, Frankfurt, Germany
[4] Univ Oxford, Churchill Hosp, Oxford, England
[5] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[6] Nerviano Med Sci, Nerviano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4593
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Lim, Ho Yeong
    Oh, Do-Youn
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Results of a Phase I/II Trial of Amrubicin (AMR) in Combination with Cisplatin (CDDP) as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hattori, Yoshihiro
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Negoro, Shunichi
    Hida, Toyoaki
    Takeda, Koji
    Masuda, Noriyuki
    Nakagawa, Kazuhiko
    Yokota, Soichiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S386 - S386
  • [43] A phase I/II trial of intraperitoneal (IP) cisplatin (CDDP) with IP gemcitabine (GEM) in patients (pts) with epithelial ovarian cancer.
    Sabbatini, P
    Aghajanian, C
    Hensley, M
    Tong, W
    Soignet, S
    Hoskins, W
    Flaherty, CO
    Pezzulli, S
    Barakat, R
    Spriggs, D
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [44] Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
    Seto, T.
    Ichinose, Y.
    Yamamoto, N.
    Kaira, K.
    Negoro, S.
    Hida, T.
    Takeda, K.
    Masuda, N.
    Yokota, S.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).
    El Dika, Imane H.
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Germino, Joseph
    O'Reilly, Eileen Mary
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] LINIFANIB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS: A PHASE 2 TRIAL
    Toh, Han-Chong
    Chen, Pei-Jer
    Carr, Brian I.
    Knox, Jennifer J.
    Gill, Sharlene
    Qian, Jiang
    Qin, Qin
    Ricker, Justin L.
    Carlson, Dawn M.
    Yong, Wei Peng
    HEPATOLOGY, 2010, 52 (04) : 1166A - 1166A
  • [47] Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Ueno, Hideki
    Nakachi, Kohei
    Morizane, Chigusa
    Kondo, Shunsuke
    Shimizu, Satoshi
    Kojima, Yasushi
    Suzuki, Takuya
    Tamai, Toshiyuki
    O'Brien, James P.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [48] Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) -: Results of a phase II study
    Louafi, Samy
    Boige, Valerie
    Ducreux, Michel
    Bonyhay, Luminita
    Mansourbakht, Touraj
    de Baere, Thierry
    Asnacios, Amani
    Hannoun, Laurent
    Poynard, Thierry
    Taieb, Julien
    CANCER, 2007, 109 (07) : 1384 - 1390
  • [49] Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT)
    Cohn, Allen Lee
    Kelley, Robin Katie
    Yang, Tsai-Shen
    Su, Wu-Chou
    Verslype, Chris
    Ramies, David A.
    Lee, Yihua
    Shen, Xiaodong
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [50] A phase II study of the efficacy and safety of irinotecan in combination with capecitabine as first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma (HCC)
    Mok, Tony S. K.
    Yang, Tsai-Shen
    Chao, Yee
    Wang, Cheng-Hsu
    Kang, Yoon Koo
    Park, Joon Oh
    Kim, Jun Suk
    Liu, Mei-Ching
    Walsh, Veronica
    Leung, Thomas
    ANNALS OF ONCOLOGY, 2004, 15 : 232 - 232
12345